PHI AB’s warrant exercise registered with the Swedish Companies Registration Office

Phase Holographic Imaging PHI AB (“PHI” or the “Company”) today announces that the new shares from the exercise of warrants of series TO 3 have been registered with the Swedish Companies Registration Office.

On 2 May 2023, the exercise period for warrants of series TO 3, which were issued in connection with PHI’s rights issue of units in 2022, ended. As a result of the warrant exercise, 3,201,739 new shares have now been registered with the Swedish Companies Registration Office. The directed share issue of a total of 163,666 shares to the underwriter in connection with the warrant exercise is estimated to be registered shortly.

Conversion of interim shares to ordinary shares takes place around 29 May 2023 and are expected to be available on each subscriber's account around 31 May 2023. The total number of shares in the Company after the exercise of warrants of series TO 3 and the directed share issue to the underwriter will amount to 23,818,105 and the share capital will amount to SEK 4,763,621.

For more information about the warrants of series TO 3, please contact:

Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
Web: www.sedermera.se

For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

Phase Holographic Imaging (PHI) develops instrumentation and software for time-lapse cytometry. The products are used for long-term quantitative analysis of the dynamics of live cells, particularly significant in the research of cancer, as well as in the treatment of inflammatory and autoimmune diseases. The products are sold globally through the company's distributors. The company is based in Lund, Sweden, and in Boston, Massachusetts.